Sanela Bilic
International Drug Development(FR)Drake University(US)
Publications by Year
Research Areas
Ovarian cancer diagnosis and treatment, Monoclonal and Polyclonal Antibodies Research, Multiple Myeloma Research and Treatments, HER2/EGFR in Cancer Research, CAR-T cell therapy research
Most-Cited Works
- → Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma(2018)282 cited
- → Prognostic gene expression signature for high-grade serous ovarian cancer(2020)170 cited
- → Bioanalysis of Antibody–Drug Conjugates: American Association of Pharmaceutical Scientists Antibody–Drug Conjugate Working Group Position Paper(2013)164 cited
- → A Phase IB multicentre dose‐determination study of BHQ880 in combination with anti‐myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal‐related events(2014)154 cited
- → Inhibition of tumorigenesis driven by different Wnt proteins requires blockade of distinct ligand-binding regions by LRP6 antibodies(2010)153 cited
- → Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody® targeting the DR5 receptor(2015)150 cited